Wednesday, 28 Jun 2017


Elimination of Senescent Chondrocytes Reduces Post-Traumatic Osteoarthritis

A study in the April 24 issue of Nature Medicine suggests that senescent cells in the joint contribute to age-related degenerative disease and that their removal can abrogate disease. 

Best to Rehab at Home Following Joint Replacement

New York Times article sheds light on recent evidence suggesting that those undergoing hip or knee replacement will do just as well with home therapy compared to inpatient rehabilitation following surgery.

Pregnancy Flares in RA and Spondylitis

Despite the folklore, not all women with arthritis who become pregnant will improve or go into remission.  Recent studies have suggested that up to one-third of RA patients will flare during pregnancy.

This issue has been further examined in a cohort of 136 pregnant patients with RA and axial spondyloarthritis (axSpA) who were prospectively followed before, during, and after pregnancy.

EULAR/EFORT Taskforce on the Management of Fragility Fractures

The morbidity associated with osteoporosis-related fragility fractures imposes tremendous socioeconomic and medical impact on patients and society.

Consensus on OP Drug Holidays

Extending bisphosphonate treatment beyond 3–5 years does not confer additional benefit in low-risk populations. Treatment re-initiation (usually 1–3 years after bisphosphonate withdrawal) depends on risk factors, new fractures and bone mineral density. The evidence regarding denosumab discontinuation is limited but caution is advised, as there may be a “rebound effect” with regard to fractures.

FDA Approves Renflexis as Second Infliximab Biosimilar

On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD.  In early developmental trials this agent was also called SB2.

The RheumNow Week in Review – 21 April 2017

Dr. Jack Cush reviews highlights from the past week on

Paradoxical Toxicities with TNF Inhibitors

Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.

Inconsistent ESR & CRP in Spondylitis Patients


Patients with active axial spondyloarthritis (axSpA) can lack evidence of inflammation on magnetic resonance imaging (MRI) but may develop evidence of inflammation over time.

Anti-IL-23 Therapy Effective in Crohn's Disease

Lancet has reported the results of risankizumab, an interleukin-23 (IL-23) inhibitor, in Crohn's disease. Risankizumab is a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, and is being developed for Crohn's disease. Other IL-23 inhibitors are currently under tudy for inflammatory bowel disease, psoriasis, psoriatic arthritis, and spondyloarthritis.

The Cost of Not Taking Medicine

The NY Times points out "there is is an out-of-control epidemic in the United States that costs more and affects more people than any disease Americans currently worry about. It’s called nonadherence to prescribed medications, and it is — potentially, at least — 100 percent preventable by the very individuals it afflicts.

FDA Delays Baricitinib Decision

Eli Lilly and Company and Incyte Corporation announced today that the U.S. Food and Drug Administration (FDA) has delayed its' decision on baricitinib by issuing a complete response letter for baricitinib's New Drug Application. 

Lilly and Incyte originally submitted the NDA for baricitinib to the FDA in January 2016.